Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Metabolex grants Sanofi rights to Phase II diabetes candidate; deal ends

Executive Summary

Metabolex Inc. (therapies for metabolic diseases) has granted Sanofi-Aventis exclusive worldwide rights to its MBX2982, a G-protein coupled receptor 119 (GPR119) agonist that is in Phase IIa trials for Type II diabetes.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register